A phase I/II, feasibility study of B43-PAP immunotoxin in combination with standard induction chemotherapy in children and adolescents with relapsed CD19-positive B-lineage acute lymphoblastic leukemia (B-ALL).
Phase of Trial: Phase I/II
Latest Information Update: 25 May 2016
At a glance
- Drugs Taplitumomab paptox (Primary)
- Indications Acute lymphoblastic leukaemia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 25 May 2016 New trial record